Table 3.
Isolate # | AMP | GEN | ERY | TET | MXF | NIT | DAPa | LIZ | TEC | VAN | vanA | vanB |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EM0085 | S | S | R | R | S | S | N | S | S | R | – | – |
EM0176 | S | S | R | S | S | I | N | S | S | R | + | – |
EM3113 | S | S | R | R | S | S | N | S | S | R | – | – |
EM0476 | S | S | S | S | I | S | N | S | R | R | + | – |
EM2016 | S | S | R | R | S | S | S | S | S | R | – | + |
EM0040 | S | S | S | S | R | S | N | S | S | R | – | – |
EM0049 | S | S | S | S | R | S | N | S | S | R | + | – |
EM0149 | S | S | S | S | I | S | S | S | S | R | – | – |
EM0477 | S | S | S | S | I | S | S | I | R | R | + | – |
EM1161 | S | S | S | S | S | S | S | S | S | R | – | + |
EM0162 | S | S | I | S | R | S | N | R | R | R | + | – |
EM0074 | S | S | S | S | I | S | S | S | S | R | – | – |
EM0014 | S | S | S | S | S | S | S | S | S | R | – | – |
EM0116 | S | S | S | S | S | S | S | S | S | R | – | + |
EM0022 | S | S | S | S | S | S | S | S | S | R | – | – |
EM0056 | S | S | S | S | S | S | S | S | S | R | – | – |
EM0099 | S | S | S | S | S | S | N | S | S | R | – | – |
EM0010 | S | S | S | S | S | S | S | S | S | R | + | – |
EM0018 | S | S | S | S | S | S | S | S | S | R | – | – |
EM1009 | S | S | S | S | S | S | S | S | S | R | – | – |
Total R/+ (%) | 0 | 0 | 04 (20) | 03 (15) | 03 (15) | 0 | 0 | 01 (5) | 03 (15) | 20 (100) | 06 (30) | 03 (15) |
E. casseliflavus & Enterococcus gallinarum are intrinsically resistant to vancomycin
AMP ampicillin, VAN vancomycin; aGEN high level gentamicin, ERY erythromycin, TET tetracyclin, MXF moxifloxacin, NIT nitrofurantoin, DAP daptomycin, TEC teicoplanin, LIZ linezolid, S Susceptible, I Intermediate, R Resistant, N non-susceptible; −, Negative; +, Positive